• 1
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 summary of a workshop. Gastroenterology 2001; 120: 18281853.
  • 2
    Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 17571762.
  • 3
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. HEPATOLOGY 1998; 27: 16701677.
  • 4
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou, C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. HPATOLOGY 2000; 32: 847851.
  • 5
    Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398402.
  • 6
    Bonino F, Hoyer B, Nelson J, Engle R, Verme G, Gerin J. Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. HEPATOLOGY 1981; 1: 386391.
  • 7
    Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Reviews 1995; 1: 736.
  • 8
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588591.
  • 9
    Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91: 40774081.
  • 10
    Fang ZL, Yang J, Ge X, Zhuang H, Gong J, Li R, Ling R, Harrison TJ. Core promoter mutations (A1762T and G1764A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J Med Virol 2002; 68: 3340.
  • 11
    Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. HEPATOLOGY 2000; 32: 11451153.
  • 12
    Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis b virus during the course of lamivudine therapy. HEPATOLOGY 2000; 32: 11631169.
  • 13
    Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. HEPATOLOGY 2002; 36: 186194.
  • 14
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001; 34: 785791.
  • 15
    Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. HEPATOLOGY 2000; 32: 10781088.
  • 16
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulus V, Hadziyannis SJ. Course of virologic breakthrough under long-term lamivudine in HBeAg-negative pre-core mutant HBV liver disease. HEPATOLOGY 2002; 36: 219226.
  • 17
    Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003; 23: 8188.
  • 18
    Smedile A, Rizzetto M, Denniston K, Bonino F, Wells F, Verme G, Consolo F, et al. Type D hepatitis: the clinical significance of hepatitis D virus RNA in serum as detected by a hybridization-based assay. HEPATOLOGY 1986; 6: 12971302.
  • 19
    Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness and structural proteins of six strains of hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489503.
  • 20
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. HEPATOLOGY 2001; 33: 751757.
  • 21
    Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 37293734.
  • 22
    Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702707.
  • 23
    Bartholomeusz A, Locarnini SA. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. International Antiviral News 1997; 5: 123124.
  • 24
    Naoumov NV, Chokshi S, Smith H, Williams R. Emergence and characterization of lamivudine resistant hepatitis B variant. HEPATOLOGY 1996; 24: 282A.
  • 25
    Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in fingers subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299: 8899.
  • 26
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and take over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. HEPATOLOGY 1998; 27: 17111716.
  • 27
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 2022.
  • 28
    Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)ddC (3TC) resistance. Biochem Pharmacol 1998; 55: 15671572.
  • 29
    Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi RF, Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. International Antiviral News 1998; 6: 167169.
  • 30
    Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. HEPATOLOGY 2000; 31: 13181326.
  • 31
    Kao JH, Chen PJ, Lai MY, Chen DS. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002; 68: 216220.
  • 32
    Sallam TA, Tong CY. Two distinct types of hepatitis B virus core promoter variants in Yemeni blood donors. J Med Virol 2002; 68: 328334.
  • 33
    Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 47714779.
  • 34
    Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430439.
  • 35
    Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, Legendre C, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 20902094.